BioSpace News Archive

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that Age

Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product.

The global tinnitus market exhibited impressive growth in the recent past as the number of people suffering from tinnitus has been increasingly continuously.

Hereditary angioedema develops in the most common areas of the body and results in recurrent episodes of severe swelling.

Transparency Market Research has published a new report on the HIV/AIDS diagnostics market for the forecast period of 2019–2027.

The global drug-eluting stents market is anticipated to be driven by an increase in the number of DES system approvals by various regulatory authorities, such as the Food and Drug Administration, Japanese Ministry of Health, and China Food and Drug Administration, and the ever-increasing prevalence of cardiovascular diseases.